Ote Pharma Sol B.V. – FDA EIR, Sep 15, 2023

A surveillance inspection of pharmaceutical manufacturer Ote Pharma Sol B.V. was conducted by the U.S. Food and Drug Administration (FDA) from September 11-15, 2023. This announced inspection was part of the FY23 Foreign Drug Inspection plan, adhering to the regulatory framework outlined in CP 7356.002, "Drug Manufacturing Inspections." Ote Pharma Sol B.V. operates as a manufacturer of sterile solutions and was undergoing its initial FDA inspection. The comprehensive assessment covered key areas including the Quality System, Facilities and Equipment System, Materials System, Production System, Packaging and Labeling System, and Laboratory System. During the inspection, FDA investigators reviewed various essential documents such as Corrective and Preventive Actions (CAPAs), Out-of-Specification/Out-of-Trend (OOS/OOT) investigations, deviation reports, batch records, Standard Operating Procedures (SOPs), annual product reviews, machine qualifications and calibrations, and laboratory notebooks. Crucially, at the conclusion of the inspection, no Form FDA 483 was issued, indicating that no significant observations or violations requiring immediate corrective action were identified. Consequently, the inspection was classified as "No Action Indicated" (NAI). This signifies that the firm was found to be operating in substantial compliance with FDA regulations at the time of the inspection. No specific required actions were mandated by the FDA based on this report, beyond routine follow-up as assigned. Ote Pharma Sol B.V. remains registered with the FDA, and no inspection refusals occurred.